Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion - CNBC

By Anonymous User · February 23, 2026

Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion  CNBCBiotech M&A heats up with Gilead-Arcellx deal  AxiosUS Premarket Movers: Arcellx, Domino’s, MoonLake, Vanda, Veris  Bloomberg.comGilead shows belief in its partner’s cancer treatment with $7.8 billion buyout  MarketWatchGilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion  The Wall Street Journal